Review
Pharmacology & Pharmacy
Hae Jin Kee, Inkyeom Kim, Myung Ho Jeong
Summary: This article provides an overview of the pathogenesis of hypertension, current anti-hypertensive drugs, and the need for novel drugs. It focuses on the role and regulatory mechanisms of HDACs in hypertension and discusses the progress in developing HDAC inhibitors as potential therapeutic targets.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Oncology
Ioanna Savvidou, Tiffany Khong, Sophie Whish, Irena Carmichael, Tara Sepehrizadeh, Sridurga Mithraprabhu, Stephen K. Horrigan, Michael de Veer, Andrew Spencer
Summary: This study demonstrates the significant anti-multiple myeloma effects of a combination therapy of low dose panobinostat and beta-catenin inhibitor Tegavivint both in vitro and in vivo, with minimal toxicity. This novel combination could potentially benefit myeloma patients that have exhausted mainstream therapeutic options.
Review
Oncology
Darren Pan, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier, Joshua Richter
Summary: This study retrospectively analyzed the efficacy and safety of Panobinostat-based combinations in heavily pretreated multiple myeloma patients. The results showed that Panobinostat, when combined with other drugs, achieved modest response rates but had significant toxicities in this patient population.
SEMINARS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Svetlana Demyanenko, Valentina Dzreyan, Svetlana Sharifulina
Summary: Cerebral ischemia is the second leading cause of death worldwide, requiring multimodal stroke therapy. Histone deacetylase inhibitors have shown to be effective in protecting the brain from ischemic damage by inducing neurogenesis and angiogenesis in damaged brain areas, promoting functional recovery after stroke.
Article
Agricultural Engineering
Xuefeng Lu, Tae Kyung Hyun
Summary: Post-translational histone modifications, such as histone acetylation, play key roles in regulating gene expression in plant growth, development, and stress responses. The research found that HDAC inhibitors led to hyperacetylation of histone H3, enhancing MeJA-induced ginsenoside production in ginseng adventitious roots. Additionally, the study identified specific PgHDACs that may serve as crucial factors in controlling MeJA-induced ginsenoside production.
INDUSTRIAL CROPS AND PRODUCTS
(2021)
Review
Oncology
Amandine Badie, Christian Gaiddon, Georg Mellitzer
Summary: Our understanding of the identity of many cancers has greatly increased in recent years, leading to progress in early detection and treatment options. However, gastric cancer remains poorly treated with low survival rates. The lack of possibilities for early detection and the variations between tumors of gastric cancer patients are major challenges. Histone Deacetylases (HDACs) have been identified to be potentially related to gastric cancer. In this review, we summarize the current knowledge on the role of HDACs in gastric cancer development and their potential as early detection markers and targets for new treatment options.
Article
Genetics & Heredity
E. Chen, NanJing Liu, Yan Zhao, Min Tang, LiPing Ou, XiaoHou Wu, ChunLi Luo
Summary: The study found that panobinostat can enhance the acetylation of lys9 of histone 3 and reverse the expression of hepaCAM through inhibiting HDACs activity in PCa LNCaP and DU145 cells. Furthermore, the combination of Ad-hepaCAM with panobinostat synergistically inhibits the growth of LNCaP and DU145 cells, potentially by down-regulating the expression of CCND1 and PCNA.
Article
Oncology
Melanie R. Muller, Aaron Burmeister, Margaretha A. Skowron, Alexa Stephan, Felix Bremmer, Gamal A. Wakileh, Patrick Petzsch, Karl Kohrer, Peter Albers, Daniel Nettersheim
Summary: This study identified seven drugs targeting epigenetic modifiers to treat cisplatin-resistant GCTs. Mass spectrometry-based analyses revealed effects beyond the expected mode-of-action of each drug, suggesting a wider spectrum of activity. Additionally, the study characterized the effects of each drug on the transcriptome of GCT cells and identified common deregulations in gene expression of ion transporters and DNA-binding factors.
CLINICAL EPIGENETICS
(2022)
Article
Oncology
Bryan J. Neth, Samantha N. Balakrishnan, Ivan D. Carabenciov, Joon H. Uhm, David J. Daniels, Sani H. Kizilbash, Michael W. Ruff
Summary: This article reports the clinical outcomes of panobinostat in adults with H3 K27M-mutant DMG. The study found that panobinostat was well-tolerated at the dosage schedule described, with no serious adverse effects observed throughout the study period. The median overall survival was 42 months, and the median progression-free survival was 19 months.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Review
Oncology
Fengyi Guo, Hongjing Wang
Summary: This review summarizes the classification and mechanisms of action of histone deacetylase and the clinical application of their inhibitors in ovarian cancer. Histone deacetylase inhibitors show promising potential as anti-cancer drugs, and combination therapy with other anticancer drugs for synergistic effects can improve efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Robert Jenke, Nina Ressing, Finn K. Hansen, Achim Aigner, Thomas Buch
Summary: Epigenetic changes can drive cancer malignancy, while histone deacetylase inhibitors (HDACis) hold promise as anticancer drugs due to their ability to target multiple pathways relevant to the disease.
Review
Oncology
Jason Lin, Shang-Chuen Wu
Summary: This review examines the role of protein serotonylation in transcriptional regulation, its potential impact on the epigenetic landscape, and its implications in lung and other types of cancer. The review discusses the mechanistic details of serotonylation and its connections to the epigenome, as well as the role of transglutaminase 2, in order to guide the development of optimized histone deacetylase inhibitor designs or combination therapies for cancer treatment.
Review
Cell Biology
Iason Psilopatis, Kleio Vrettou, Florian Nima Fleckenstein, Stamatios Theocharis
Summary: Endometriosis is a chronic disorder that affects many women globally. Histone deacetylases (HDACs) play a role in gene transcription by regulating chromatin relaxation. This comprehensive review examines the impact of histone modifications and therapeutic targeting, specifically focusing on HDACs and their inhibitors in endometriosis. The five most studied HDAC enzymes, HDAC1, HDAC2, HDAC3, Sirtuin 1, and Sirtuin 3, have been found to influence the pathophysiology of endometriosis. Both established and novel HDACIs show promise as effective anti-endometriotic drugs. Overall, histone modifications and therapeutic targeting have a significant impact on endometriosis.
Article
Immunology
Martina Mazzocchi, Susan R. Goulding, Noelia Morales-Prieto, Tara Foley, Louise M. Collins, Aideen M. Sullivan, Gerard W. O'Keeffe
Summary: The peripheral administration of Class IIa-specific HDIs may have neuroprotective effects in Parkinson's disease.
BRAIN BEHAVIOR AND IMMUNITY
(2022)
Article
Biochemistry & Molecular Biology
Yiming Chen, Lihui Zhang, Lin Zhang, Qixiao Jiang, Lei Zhang
Summary: Through structural modification, a HDAC inhibitor (I13) with high anticancer activity was discovered, showing promising inhibitory and antiproliferative potencies in in vitro investigations and cancer cell screenings. The compound also demonstrated potential for inhibiting tumor growth in animal models.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
(2021)